| Previous Close | 32.890 |
| Open | 32.790 |
| Bid | 32.930 x 7700 |
| Ask | 32.940 x 9700 |
| Day's Range | 32.690 - 32.955 |
| 52 Week Range | 29.830 - 37.390 |
| Volume | 7,822,487 |
| Avg. Volume | 20,276,650 |
| Market Cap | 196.37B |
| Beta | 1.07 |
| PE Ratio (TTM) | 27.70 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.28 (3.87%) |
| Ex-Dividend Date | 2017-08-02 |
| 1y Target Est | N/A |
- Financial Times•48 minutes ago
[$$] AstraZeneca: transcendental agitation
Philosopher Blaise Pascal never faced proof he was wrong to believe in God. AstraZeneca's Pascal Soriot has discovered his faith in the Mystic cancer drug trial really was misplaced. A failure of a key ...
- InvestorPlace•3 hours ago
Gilead Sciences, Inc. (GILD) Stock Has Tremendous Potential Even Post-Rally
For the past few months, Gilead Sciences, Inc. (NASDAQ:GILD) could not fulfill the technical upside promise. Last night, GILD report earnings and the stock is spiking toward $76. Click to Enlarge Coming into the earnings, sentiment had also shifted in favor of better days to come from GILD stock, and I am one who likes to trade with the market sentiment.
- TheStreet.com•4 hours ago
Alexion Spikes on Q2 Earnings Blowout Providing Positive Signs for Rest of Sector -Biotech Movers
Alexion Pharmaceuticals, United Therapeutics and Gilead Sciences were among the biotech stock movers in premarket trading on July 27.
